SAN DIEGO, Feb. 6 /PRNewswire/ -- MediciNova, Inc., a specialty
pharmaceutical company that is publicly traded on the Hercules Market of the
Osaka Securities Exchange (Code Number: 4875), today announced completion of
enrollment of 297 patients with relapsing multiple sclerosis (MS) in its
Phase II clinical trial of MN-166.
MN-166 is a novel, orally administered compound being evaluated for the
treatment of MS. In July 2005, MediciNova initiated a randomized,
double-blind, placebo-controlled multi-center Phase II clinical trial of
MN-166 in MS patients in Eastern Europe. Two hundred and ninety-seven (297)
patients have been randomized to receive placebo or one of two doses of MN-166
in this trial. Efficacy data is expected after one year of treatment (in this
two year trial) in 1Q07.
MN-166 inhibits leukotriene activity, phosphodiesterases and nitric oxide
synthase, all inflammatory mechanisms known to be involved in MS. Recently,
MN-166 was found to have beneficial effects in several pilot clinical trials
conducted in MS patients in Japan. These findings led to the issuance of a
new U.S. method of use patent for MN-166 in 2002.
"MN-166 may be an effective new approach to treating MS with the added
advantage of oral dosing. Rapid completion of enrollment in this relatively
large trial demonstrates our commitment to advancing our clinical programs
efficiently though the Phase II proof-of-concept stage and beyond," said
Yuichi Iwaki, M.D., Ph.D., Executive Chairman and Acting CEO of MediciNova,
MediciNova acquired the rights to MN-166 from Kyorin Pharmaceutical Co.
Ltd. for global markets excluding Japan, China, Taiwan and South Korea. For
the past 16 years, MN-166 has been marketed in Japan and South Korea as
Ketas(R) for the treatment of asthma and cerebrovascular disorders. Data from
the existing clinical trial and post-marketing surveillance databases, which
includes treatment of an estimated 3.2 million patients with these disorders,
indicate that Ketas(R) is well tolerated.
MediciNova, Inc. is a publicly traded specialty pharmaceutical company
focused on accelerating the global development and commercialization of
innovative pharmaceutical products. MediciNova's pipeline, which includes
several compounds in clinical testing, targets a variety of prevalent medical
conditions, including cancer, asthma, Generalized Anxiety Disorder, multiple
sclerosis, interstitial cystitis, preterm labor and urinary incontinence. For
more information on MediciNova, Inc., please visit www.medicinova.com.
This press release may contain "forward looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements include statements regarding clinical trials supporting efficacy of
one of our product candidates as well as the potential novelty of that
candidate as a treatment for disease. These statements are based on certain
assumptions made by the Company's management that are believed to be
reasonable at the time. Such statements are subject to a number of risks and
uncertainties, many of which are beyond the control of the Company, including
the results of clinical studies and other risks and uncertainties, including
those described in the Company's filings with the Securities and Exchange
Commission. These assumptions, risks and uncertainties could cause the
Company's actual results to differ materially from those implied or expressed
by the forward-looking statements.
SOURCE MediciNova, Inc.